Long-term effects of denosumab: a 10-year single-center retrospective study
Authors:
- Federico AldegheriFAFederico Aldegheri
- Matteo AppoloniMAMatteo Appoloni
- Nicolò PassoniNPNicolò Passoni
- Vittorio ZibordiVZVittorio Zibordi
- Maurizio RossiniMRMaurizio Rossini
- Davide GattiDGDavide Gatti
- Giovanni AdamiGAGiovanni Adami
- Francesco PollastriFPFrancesco Pollastri
- Angelo FassioAFAngelo Fassio
- Ombretta ViapianaOVOmbretta Viapiana
Open Access
- 19 August 2026
- journal article
- research article
- Published by Springer Nature in Archives of Osteoporosis
- Vol. 21 (1) , 123
Abstract
Summary: Osteoporosis weakens bones and increases the risk of fractures. Denosumab is a medication that reduces bone loss and increases bone mineral density (BMD). In this real-world study, we followed patients who received denosumab every 6 months for 10 years. We found that bone density continued to improve throughout treatment. People who had taken bisphosphonates before starting denosumab responded just as well in the long term. Blood tests showed stable reduction of bone turnover markers. Background: Denosumab produces durable BMD gains and low fracture rates in clinical trials, but long-term real-world evidence is limited, especially on the effect of prior bisphosphonate exposure and characteristics of patients who fracture during therapy. Methods: We conducted a 10-year single-center real-world retrospective study including patients receiving continuous denosumab 60 mg every 6 months. Clinical, biochemical, and densitometric data were extracted from an institutional electronic database. Longitudinal changes in BMD at total hip, lumbar spine, and femoral neck were analyzed using linear mixed-effects models adjusted for baseline BMD, age, baseline severe vertebral fractures, and glucocorticoid exposure. Bone turnover markers (CTX, ALP, PTH) were analyzed with mixed-effects models adjusted for renal function. Results: A total of 145 patients were included (mean age 70.9 years; 95.9% women). Over 10 years, BMD increased significantly at all skeletal sites: +12.9% at the total hip, + 16.3% at the lumbar spine, and +6.0% at the femoral neck. CTX and ALP showed marked and sustained reduction, whereas PTH remained stable over time. Prior bisphosphonate exposure did not modify long-term BMD trajectories at any site, and group differences in CTX converged after treatment initiation. Patients who sustained fractures showed significantly attenuated lumbar spine BMD gains, while hip sites displayed similar trajectories to non-fractured patients. Conclusions: In a real-world setting, continuous denosumab therapy for 10 years produced robust and sustained BMD gains, accompanied by a durable and stable reduction in bone turnover. Prior bisphosphonate exposure influenced only early biochemical differences and did not affect decade-long BMD responses.Keywords
Funding Information
- Università degli Studi di Verona
This publication has 39 references indexed in Scilit:
- A systematic review and meta-analysis of sequential treatment strategies for osteoporosisOsteoporosis International, 2025
- Trends in serum phosphate, calcium, and parathyroid hormone levels according to renal function following denosumabOsteoporosis International, 2025
- Risk factors for nonresponse to 2 years of denosumab administration in patients with osteoporosis: A retrospective single‐center cohorts studyHealth Science Reports, 2024
- The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studiesOsteoporosis International, 2018
- The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension studyOsteoporosis International, 2015
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trialOsteoporosis International, 2012
- Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumabJournal of Bone and Mineral Research, 2012
- Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fracturesJournal of Bone and Mineral Research, 2011
- Effects of denosumab on fracture and bone mineral density by level of kidney functionJournal of Bone and Mineral Research, 2011
- Determinants of Bone Turnover Markers in Healthy Premenopausal WomenCalcified Tissue International, 2008